MicroRNA biomarkers for earlier prostate cancer detection
Prostate cancer is among the most commonly diagnosed cancers in Australia, and identifying clinically significant disease before symptoms develop remains a priority. PSA testing estimates risk but is not a cancer test by itself. Benign enlargement, prostatitis and normal variation can alter PSA, while some aggressive tumours produce little PSA. MicroRNA biomarkers are being studied as complementary molecular signals.
MicroRNAs are short, non-coding RNAs that regulate gene expression after transcription. They can be measured in blood or urine, including molecules protected in extracellular vesicles such as exosomes. This stability makes them attractive for specimen analysis. However, tumour and non-tumour cells both release microRNAs, so a concentration change does not automatically identify where it originated.
An effective early-detection marker must detect important disease, work across diverse populations, survive routine specimen handling and improve a clinical decision. Some microRNAs are associated with advanced disease or prognosis, which is not the same as detecting localised cancer. A test developed against healthy controls may perform poorly among men with benign prostatic enlargement, prostatitis or an abnormal PSA.
For Australian patients and clinicians, the question is where these assays could fit around PSA assessment, examination, repeat testing, risk calculators, multiparametric MRI and biopsy. Evidence does not yet support replacing standard evaluation with an unvalidated microRNA panel. The promising role is incremental: identify men who need earlier review or avoid unnecessary investigations without weakening safeguards against missed disease.
Why microRNAs are being studied
Prostate cancer is heterogeneous. Some tumours respond to treatment, while others invade or metastasise despite a small primary lesion. MicroRNAs influence growth, androgen-receptor signalling, apoptosis and immune responses. Their altered expression in tumour tissue may therefore reveal biology that total PSA concentration cannot.
A practical attraction is that blood is routinely collected and urine needs no anaesthesia or hospital appointment. Vesicle-associated profiles may enrich tumour-derived material, yet isolation adds complexity and variation. No sample type or extraction method is inherently superior; each needs testing in the population and workflow where it would be used.
Candidate signals and their limits
miR-21 is frequently reported as increased in serum or plasma and can be measured with established quantitative PCR methods. miR-141 and miR-375 have been linked to aggressive or advanced disease in some cohorts. Candidates including miR-17-3p, miR-106b, miR-145 and miR-183 have been studied in urine, serum and tissue.
Performance varies with sample type, assay design and participant selection. A marker may separate cancer from healthy controls yet add little to PSA among men with benign enlargement. A significant result from a small case-control study also needs prospective validation in the real diagnostic pathway. Until then, “early marker” is a research description, not a guarantee of patient benefit.
What Australian practice needs from these tests
In Australia, PSA is usually discussed through primary care rather than a single national screening programme. Guidance generally treats testing as an individual decision based on age, family history, ancestry, previous results and the risks of over-investigation. Men with a strong family history or Black African ancestry may need a different discussion. A population average cannot replace this clinical context.
Medicare rebates cover many standard services, while commercial pathology is a major part of the local market, including laboratories in Melbourne, Sydney and Brisbane. A research microRNA assay may be outside routine Medicare coverage, and sample transport from rural and remote areas can affect cost and turnaround. Aboriginal and Torres Strait Islander men need culturally safe access and appropriately designed local evidence. Patients can use general diagnostic resources to prepare questions for their GP.
| Candidate | Sample often studied | Reported prostate-cancer signal | Current limitation |
|---|---|---|---|
| miR-21 | Serum, plasma or vesicles | Often higher in prostate cancer | Inflammation and tissue injury can also raise it |
| miR-141 | Serum or plasma | Higher in some advanced cancers | Inconsistent performance for early localised disease |
| miR-375 | Serum or plasma | Associated with aggressive disease in selected cohorts | Variable relationship with tumour grade |
| miR-17-3p and miR-106b | Urine or serum | Possible signals associated with high-grade disease | Collection and normalisation differences |
| miR-145 and miR-183 | Urine, serum or tissue | Reduced or altered expression in tumour tissue | Limited cross-platform replication |
Avoiding false reassurance and unnecessary biopsies
A biomarker used in a low-prevalence setting can look strong in a laboratory but cause many false positives. Positive predictive value depends on prevalence and specificity. If many men have benign conditions, an imperfect marker may trigger repeat tests, MRI or biopsy without improving outcomes. This matters in Australia, where active surveillance and watchful waiting are important for low-risk disease.
Urine collection and timing matter. Infection, inflammation, ejaculation, exercise, cycling and contamination can alter a profile; blood results can be affected by haemolysis, platelet contamination and processing delays. The paediatric reflux guidelines illustrate a broader urology principle: urinary findings need symptoms, age and alternative diagnoses alongside them. The same caution applies to prostate biomarkers.
Imaging has a defined role when the clinical question is specific. The journal's preoperative imaging guidance in living kidney donor evaluation shows how targeted imaging answers anatomical and functional questions. Prostate MRI helps assess lesion location, extent and the likelihood of clinically significant cancer, but it does not identify every molecular subtype. A microRNA assay should complement, not pretend to replace, anatomical assessment.
From laboratory validation to a usable assay
Reliable biomarkers need analytical validation: accurate measurement, defined detection limits, suitable normalisation and reproducibility across operators and instruments. Serum and plasma are not interchangeable, and collection tubes, centrifugation and processing time can alter vesicle profiles. Urine assays need consistent collection and controls for concentration and contamination. A research result may not transfer cleanly to a routine pathology network.
Clinical validation should enrol men who would actually receive testing, use an appropriate reference standard, and report sensitivity, specificity, calibration and decision-curve outcomes. Panels should be compared with PSA, PSA density, risk calculators, PCA3, multiparametric MRI and PSMA PET/CT where appropriate. An Australian commercial test would need transparent accreditation, quality controls and regulatory oversight, with analysis of avoided scans, repeat tests and biopsies.
Practical guidance for patients and clinicians
Anyone considering an early-detection assay should treat it as additional evidence. Ask what population was studied, what sample and method were used, whether validation was prospective, and what follows an abnormal or indeterminate result. A GP, urologist or specialist pathology service can place the result in context. Transparent uncertainty is more useful than a single unexplained score.
Clinical teams should interpret microRNA data with PSA, examination, family history, ancestry, previous biopsies, urinary symptoms and medicines. A low-risk result should not cancel a warranted investigation, and a high-risk result should not automatically trigger invasive treatment. Follow-up may involve repeat PSA, a validated risk calculator, multiparametric MRI, specialist review or biopsy.
- Prefer evidence from independent, prospective cohorts of men undergoing routine assessment.
- Confirm sample collection methods, controls, uncertainty and laboratory quality standards.
- Combine any result with PSA, examination and relevant imaging through a clinician who can explain follow-up.
- Avoid direct-to-consumer claims that promise cancer detection without a clear evidence base or care pathway.
A measured path to earlier detection
The strongest case for microRNA biomarkers is not replacement of PSA, MRI or biopsy. It is refinement: identify an elevated-PSA subgroup needing prompt review, or reduce repeated testing when current methods are uncertain. A useful panel must show incremental value beyond current tools and work across Australian ages, ancestries, incomes and locations.
Readers can follow developments through the current and past issues of Urological Science, articles in press and open-access research, which place the topic within wider urology. Patient health information can support shared discussions, alongside advice from a GP or urologist. The immediate action is to discuss personal risk through established pathways, use validated PSA assessment and ask whether any proposed microRNA test has independent prospective validation. Follow peer-reviewed updates so innovation becomes earlier, safer and more equitable care.